M3 Stock
M3 Stock price
Key metrics
Is M3 a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.
M3 Stock Analysis
Analyst Opinions
19 Analysts have issued a M3 forecast:
Analyst Opinions
19 Analysts have issued a M3 forecast:
Financial data from M3
| Mar '25 |
+/-
%
|
||
| Revenue | 284,900 284,900 |
19%
19%
|
|
| Gross Profit | 154,364 154,364 |
10%
10%
|
|
| EBITDA | 72,504 72,504 |
1%
1%
|
EBIT (Operating Income) EBIT | 60,299 60,299 |
4%
4%
|
| Net Profit | 40,484 40,484 |
11%
11%
|
|
In millions JPY.
Don't miss a Thing! We will send you all news about M3 directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
M3, Inc. engages in the provision of medical related services through the Internet. It operates through the following segments: Medical Portal, Evidence Solutions, Overseas, Clinical Platform, and Others. The Medical Portal segment provides the medical-related marketing support and research services. The Evidence Solutions segment includes clinical research support business, medical clinical trials management, and management support business. The Overseas segment offers marketing support and research services for medical-related firms in the United States, the United Kingdom, and South Korea. The Clinical Platform segment engages in the development, sale and support of electronic medical records. The Others segment offers information services for medical institutions and prescription drug advertising business. The company was founded on September 29, 2000 and is headquartered in Tokyo, Japan.
| Head office | Japan |
| CEO | Itaru Tanimura |
| Employees | 12,100 |
| Founded | 2000 |
| Website | corporate.m3.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
